Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Oruka ...
Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is ...
Opinions expressed by Forbes Contributors are their own. Steven covers accessibility and assistive technologies. In all my briefings with Apple on AirPods over the years, one of the first things ...
Stifel has launched its coverage on pre-clinical stage biotech Oruka Therapeutics (NASDAQ:ORKA) with a buy recommendation and ...
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the ...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price ...
which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
GlobalData on MSN1mon
Netherlands move forward with Naval Group on Orka-class submarinesFrance’s Naval Group has confirmed a deal with the Royal Netherlands Navy to build four Orka-class submarines to replace the ...
Dai Nippon Printing Co., Ltd. +7.53% +34.58% Dai Nippon Printing Co., Ltd. +0.00% +0.00% ...
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback